New YorkAnd January 6 2022 /PRNewswire/ — DarioHealth Corp. announced. (Nasdaq: DRIO), the global digital therapies (DTx) market leader, announced two new contracts today to deliver its highly personalized digital therapies beginning in the first quarter of 2022.
New clients include a large Northeast regional business in the finance industry set to deploy the full Dario suite of solutions, and a contracted Northeast regional business in the food industry to deploy Dario’s digital diabetes therapeutic solution.
The Dario Digital Therapy platform provides highly personalized support for people with prediabetes, prediabetes, hypertension, weight management, and musculoskeletal and behavioral health needs through a combination of innovative technologies, digital tools, and specialized human support. Full integration across a single AI-driven behavior change engine that addresses essential health behaviors using intelligence collected from billions of data points collected over ten years of consumer engagement to create a comprehensive, seamless member experience that is proven to deliver sustainable engagement and outcomes.
“Dario captured significant momentum in the employer market during the last quarter of 2021, and we are excited to begin the year with additional agreements that will contribute to revenue in 2022. The addition of another customer to our full solutions suite is particularly exciting, as we believe that more employers will be able to The business finds value in our integrated suite of multiple terms compared to single point solutions, and we look forward to expanding our customers across the full suite this year,” Rick AndersonPresident and Managing Director of North America.
About DarioHealth Corp.
DarioHealth Corp (Nasdaq: DRIO) is a leading global digital therapy company that is revolutionizing how people with chronic diseases manage their health. DarioHealth offers one of the most comprehensive digital treatment solutions on the market – covering many chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.
Dario’s next-generation digital therapeutic platform powered by artificial intelligence supports more than just an individual’s disease. Dario provides adaptive and personalized experiences that drive behavior change through evidence-based interventions, intuitive and clinically proven digital tools, and high-quality programs and training to help individuals improve health and maintain meaningful outcomes.
Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.
The company’s cross-functional team works at the intersection of life sciences, behavioral sciences, and software technology and uses a performance-based approach to improve users’ health.
On his way to better health, Dario is doing the right thing to do the easy thing. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary note regarding forward-looking statements
This news release and related statements by DarioHealth Corp.’s representatives and partners may or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical facts may be considered forward-looking statements. For example, the company uses forward-looking statements in this press release when it discusses the expected timing for new customers to offer Dario’s platform and solutions to its users, that the agreements will contribute to 2022 revenue, the belief that employers find value in its integrated, multi-term package compared to single point solutions, and that it looks to Expand their clients across the entire group this year. Without limiting the generality of the foregoing, words such as “plan,” “project,” “possibility,” “seek,” “may,” “will,” “expect,” “believe,” “expect,” “intend, purpose” “can”, “estimate” or “continue” is to identify forward-looking statements. Readers are cautioned that certain important factors may affect the company’s actual results and could cause those results to differ materially from any forward-looking statements that may be made in this news release.Include Factors that may affect the company’s results, including but not limited to, regulatory approvals, product demand, market acceptance, the impact of competitive products and prices, product development, marketing or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and risks associated with the adequacy of current cash resources.Additional factors that could cause or contribute to differences between the company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the company’s filings with the US Securities and Exchange Commission.Readers are cautioned to That the actual results (including including, but not limited to, the timing and results of the Company’s business and organizational plans for Dario™ (as described herein) may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Logo – http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg
DarioHealth . Company Contact
Vice President of Marketing
Source: DarioHealth Corp.